Get the Stockscreener App
0.6367
1.59%
-0.0103
Pre-market:
.63
-0.0067
-1.05%
Vistagen Therapeutics Inc stock is traded at $0.6367, with a volume of 287.45K.
It is down -1.59% in the last 24 hours and up +7.21% over the past month.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
See More
Previous Close:
$0.647
Open:
$0.65
24h Volume:
287.45K
Relative Volume:
0.39
Market Cap:
$25.23M
Revenue:
$1.04M
Net Income/Loss:
$-67.50M
P/E Ratio:
-0.3312
EPS:
-1.9222
Net Cash Flow:
$-60.67M
1W Performance:
+1.05%
1M Performance:
+7.21%
6M Performance:
-85.98%
1Y Performance:
-73.58%
1-Day Range:
$0.6352
$0.6515
1-Week Range:
$0.6069
$0.6759
52-Week Range:
$0.43
$5.14
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
Name
Vistagen Therapeutics Inc
Sector
Industry
Phone
650-577-3600
Address
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare VTGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
0.6367 | 25.63M | 1.04M | -67.50M | -60.67M | -1.9222 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-17-25 | Downgrade | Maxim Group | Buy → Hold |
| Dec-17-25 | Downgrade | Stifel | Buy → Hold |
| Dec-17-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-07-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Upgrade | Maxim Group | Hold → Buy |
| Jul-22-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-22-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-22-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-20-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Initiated | Jefferies | Buy |
| Jan-04-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jun-27-18 | Initiated | Maxim Group | Buy |
| Feb-08-18 | Reiterated | Chardan Capital Markets | Buy |
| Mar-28-17 | Initiated | Maxim Group | Buy |
View All
Vistagen Therapeutics Inc Stock (VTGN) Latest News
Vistagen Therapeutics (VTGN) Q1 2026 Earnings: Narrowing Loss Beats Estimates as Pipeline Progress ContinuesExpert Market Insights - Newser
VTGN Stock Price, Quote & Chart | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Vistagen Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
VistaGen Appoints New Chief Medical Officer to Advance Pipeline - The Globe and Mail
VTGN: Fasedienol nears pivotal phase III data in SAD, with pipeline progress and cash runway into 2027 - TradingView
[Form 4] Vistagen Therapeutics, Inc. Insider Trading Activity - Stock Titan
[Form 3] Vistagen Therapeutics, Inc. Initial Statement of Beneficial Ownership - Stock Titan
Vistagen (VTGN) hires Angel S. Angelov, MD, MBA as Chief Medical Officer with option grant - Stock Titan
VTGN DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important March 16 Deadline in Securities Class ActionVTGN - TMX Newsfile
Vistagen appoints Angel S. Angelov as chief medical officer - marketscreener.com
Vistagen appoints Angel Angelov as chief medical officer By Investing.com - Investing.com Australia
Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer - Yahoo Finance
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - Insider Monkey
VTGN News | VISTAGEN THERAPEUTICS INC (NASDAQ:VTGN) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Shareholders to Connect - ACCESS Newswire
[SCHEDULE 13G/A] Vistagen Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
All News about Vistagen Therapeutics, Inc.Common Stock - The Chronicle-Journal
Vistagen to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - marketscreener.com
Vistagen Therapeutics, Inc.Common Stock (NQ: VTGN - FinancialContent
Inside Vistagen: CEO joins RBC healthcare fireside chat on May 20 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Vistagen Reports Positive 12-Month Data for Fasedienol Nasal Spray in Social Anxiety Disorder Phase 3 Trial - Minichart
Vistagen (VTGN) Reports Positive Data from Fasedienol Study for Social Anxiety - GuruFocus
VistaGen Reports Positive Long-Term Data for Fasedienol - TipRanks
Vistagen announces preliminary positive data in ongoing open-label extension portion of PALISADE-3 phase 3 study of fasedienol for the acute treatment of social anxiety disorder - marketscreener.com
Vistagen announces positive OLE safety and 4-month efficacy signals for fasedienol in social anxiety - TradingView
Vistagen (NASDAQ: VTGN) reports positive PALISADE-3 OLE results - Stock Titan
Vistagen reports preliminary data from social anxiety trial By Investing.com - Investing.com Canada
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - marketscreener.com
TradingKey - TradingKey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
2026-05-10 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Vistagen Therapeutics, Inc. (VTGN) and Encourages Investors to Learn More About the Investigation | NDAQ:VTGN | Press Release - Stockhouse
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Trial of Fasedienol Nasal Spray for Social Anxiety Disorder; Topline Results Expected Q2 2026 - Minichart
ex_558852.htm - SEC.gov
Vistagen (VTGN) completes PALISADE-4 randomized phase, eyes Q2 2026 data - Stock Titan
Vistagen (VTGN) Wraps Up Final Patient Visits in Phase 3 Anxiety Trial - GuruFocus
Vistagen completes enrollment in phase 3 anxiety trial By Investing.com - Investing.com Canada
Public-speaking challenge study ends; Vistagen data due this quarter - Stock Titan
Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Yahoo Finance
Vistagen Therapeutics, Inc. (VTGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect - ACCESS Newswire
2026-05-05 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Connect | NDAQ:VTGN | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Vistagen Therapeutics, Inc. (VTGN) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Rosen Law Firm Urges Vistagen Therapeutics, Inc. (NASDAQ: VTGN) S - The National Law Review
Investor Notice: Robbins LLP Informs Investors of the Vistagen Therapeutics, Inc. Securities Class Action - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Vistagen Therapeutics, Inc. (VTGN) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Vistagen (VTGN) wins FDA go-ahead to advance refisolone Phase 2 hot flash studies - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop - Schubert Jonckheer & Kolbe
VistaGen appoints Nick Tressler as CFO - MSN
Vistagen Therapeutics Inc Stock (VTGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):